EUVIMEDEUVIMED entdecken
Crossref

Age-Dependent Safety Signatures of Modern Therapeutics: A Comparative Real-World Pharmacovigilance Analysis of Serious Outcomes and Disproportionality Signals

Rehan Haider 1*, Shabana Naz Shah 2, Rehab Al-Baker 3, Geetha Kumari Das 4

Pharmaceutics and Pharmacology Research · 20.03.2026 · 09 (01) · 01-12

DOI: 10.31579/2693-7247/252 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics and Pharmacology Research, online erschienen am 20.03.2026. Verfasst von Rehan Haider 1* und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Age can substantially influence the safety profile of medicines through differences in pharmacokinetics, pharmacodynamics, comorbidity burden, polypharmacy, organ function, and physiological reserve. However, adverse-event reporting patterns across age groups are not always apparent from conventional clinical studies because older adults are frequently underrepresented in clinical trials and may experience multiple concurrent exposures. The present study investigates age-dependent safety signatures of modern therapeutics using real-world pharmacovigilance data from the U.S. Food and Drug Administration Adverse Event Monitoring System (AEMS), formerly known as the FDA Adverse Event Reporting System (FAERS). The study will compare adverse-event profiles and serious clinical outcomes among younger and older adult populations and will evaluate whether specific drug–event combinations are disproportionately reported in different age groups. A structured pharmacovigilance dataset will be constructed from publicly available FDA quarterly files containing demographic characteristics, medicinal products, adverse reactions, and patient outcomes. Reports will be categorized into predefined age groups, and duplicate reports will be addressed before analysis. Descriptive statistics will characterize demographic and clinical reporting patterns. Serious outcomes, including hospitalization and death, will be compared between age groups using appropriate inferential methods. Reporting Odds Ratios (RORs), Proportional Reporting Ratios (PRRs), and complementary Bayesian disproportionality measures will be used to identify potential age-specific safety signals. The FDA describes the AEMS/FAERS quarterly files as containing demographic, drug, reaction, outcome, and reporting-source information, making the system suitable for secondary pharmacovigilance research. Disproportionality methods such as ROR, PRR, BCPNN, and MGPS are established approaches for identifying potential safety signals in spontaneous-reporting databases. The study is expected to provide a comparative safety map showing whether serious adverse-event patterns differ systematically according to age. Such findings could support age-sensitive pharmacovigilance, hypothesis generation, and prioritization of medicines requiring further safety evaluation. Because spontaneous reports cannot establish incidence or causality, identified associations will be interpreted as safety signals rather than confirmed drug-related risks.

Zitieren

APA

1*, R. H., 2, S. N. S., 3, R. A., & 4, G. K. D. (2026). Age-Dependent Safety Signatures of Modern Therapeutics: A Comparative Real-World Pharmacovigilance Analysis of Serious Outcomes and Disproportionality Signals. Pharmaceutics and Pharmacology Research, 09(01), 01-12. https://doi.org/10.31579/2693-7247/252

Vancouver

1* RH, 2 SNS, 3 RA, 4 GKD. Age-Dependent Safety Signatures of Modern Therapeutics: A Comparative Real-World Pharmacovigilance Analysis of Serious Outcomes and Disproportionality Signals. Pharmaceutics and Pharmacology Research. 2026;09(01):01-12. doi:10.31579/2693-7247/252

BibTeX
@article{2026,
  author = {1*, Rehan Haider and 2, Shabana Naz Shah and 3, Rehab Al-Baker and 4, Geetha Kumari Das},
  title = {Age-Dependent Safety Signatures of Modern Therapeutics: A Comparative Real-World Pharmacovigilance Analysis of Serious Outcomes and Disproportionality Signals},
  journal = {Pharmaceutics and Pharmacology Research},
  year = {2026},
  volume = {09},
  number = {01},
  pages = {01--12},
  doi = {10.31579/2693-7247/252}
}
Kostenlos starten →